Company Analysis
Sign in

ImageneBio, Inc. (IMA)

Nasdaq: IMA · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade3.6
◀ Past 5.0● Present 2.6▶ Future 3.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

18 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ImageneBio, Inc.’s names, not what it holds today.

Patents granted
18
18 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 5 in 2024 and 4 in 2023
Applications published
29
2 of them in 2025
Names they are printed under
5
a former name, a subsidiary
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry11
Pharmaceuticals5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Ikena Oncology, Inc. a former name
named as the applicant on its applications, in US
0 granted
21 published
Ikena Oncology, Inc. a former name
US, as the owner printed on each patent
15 granted
0 published
Arrys Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
Portsmouth Merger Sub II, LLC a subsidiary
US, as the owner printed on each patent
2 granted
0 published
Arrys Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Names not counted (1)
Inmagene, Inc.
Most of its patents print SG; this name counts in US, VG. 0 granted and 4 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,459,895MEK inhibitors and uses thereofOrganic fine chemistryIkena Oncology, Inc.
Sep 30, 202512,428,481Anti-TREM2 antibodies and related methodsPharmaceuticalsPortsmouth Merger Sub II, LLC
Aug 5, 202512,378,311Anti-MARCO antibodies and uses thereofPharmaceuticalsPortsmouth Merger Sub II, LLC
Dec 10, 202412,162,884Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitorsOrganic fine chemistryIkena Oncology, Inc.
Sep 3, 202412,077,542Indole AHR inhibitors and uses thereofOrganic fine chemistryIkena Oncology, Inc.
Jul 9, 202412,030,876Aryl hydrocarbon receptor (AHR) agonists and uses thereofOrganic fine chemistryIkena Oncology, Inc.
Mar 12, 202411,925,651TEAD inhibitors and uses thereofPharmaceuticalsIkena Oncology, Inc.
Jan 23, 202411,878,958MEK inhibitors and uses thereofOrganic fine chemistryIkena Oncology, Inc.
Sep 19, 202311,760,728Tead inhibitors and uses thereofOrganic fine chemistryIkena Oncology, Inc.
Mar 21, 202311,608,329Aryl hydrocarbon receptor (AHR) agonists and uses thereofOrganic fine chemistryIkena Oncology, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Apr 17, 20252025/0122205INDOLE AHR INHIBITORS AND USES THEREOFOrganic fine chemistryIkena Oncology, Inc.
Jan 9, 20252025/0011315ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOFOrganic fine chemistryIkena Oncology, Inc.
Oct 31, 20242024/0358723POLYMORPHIC COMPOUNDS AND USES THEREOFPharmaceuticalsArrys Therapeutics, Inc. · patent 12,295,962 granted from it
Aug 1, 20242024/0254120EP4 INHIBITORS AND SYNTHESIS THEREOFOrganic fine chemistryArrys Therapeutics, Inc.
Jun 13, 20242024/0190822MEK INHIBITORS AND USES THEREOFOrganic fine chemistryIkena Oncology, Inc. · patent 12,459,895 granted from it
May 9, 20242024/0148740COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINEPharmaceuticalsIkena Oncology, Inc.
Mar 14, 20242024/0083854TEAD INHIBITORS AND USES THEREOFOrganic fine chemistryIkena Oncology, Inc.
Feb 29, 20242024/0066040EP4 INHIBITORS AND USE THEREOFPharmaceuticalsArrys Therapeutics, Inc.
Nov 30, 20232023/0382863MEK INHIBITORS AND USES THEREOFOrganic fine chemistryIkena Oncology, Inc. · patent 11,878,958 granted from it
Sep 21, 20232023/0295147ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOFOrganic fine chemistryIkena Oncology, Inc. · patent 12,030,876 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 5 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IMA · research, not advice